May 7, 2025 03:38 PM EDT
R&D
Pharma
Manufacturing

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

Jaimy Lee

Deputy Editor

Gilead is the lat­est phar­ma com­pa­ny to an­nounce that it’s pour­ing bil­lions of dol­lars in­to its man­u­fac­tur­ing and R&D op­er­a­tions in the US.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Lan­theus culls late-stage Lil­ly-part­nered prostate can­cer ra­di­oli­gand

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times